Jefferies & Co Downgrades ResMed (RMD) to Hold
RMD Hot Sheet
Rating Summary:4 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Jefferies & Co downgrades ResMed (NYSE: RMD) from Buy to Hold. Price target increased from $50 to $53.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
You May Also Be Interested In
- Omron Launches Sleep Monitor With ResMed Technology
- ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
- UPDATE: Canaccord Genuity Downgrades Ross Stores, Inc. (ROST) to Hold; Valuation is Stretched
Create E-mail Alert Related Categories
DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
